Debrisoquine hydroxylase (CYP2D6) and prostate cancer

Cancer Epidemiology Biomarkers and Prevention

Volumn 7, Issue 12, 1998, Pages 1075-1078

  Febbo, Phillip G ^a   Kantoff, Philip W ^a,f   Giovannucci, Edward ^c,e   Brown, Myles ^a   Chang, Gloria ^a   Hennekens, Charles H ^a,b,d   Stampfer, Meir ^c,e  

^a HARVARD MEDICAL SCHOOL   (United States)

^b Division of Preventive Medicine   (United States)

^c CHANNING LABORATORY   (United States)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

^e HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^f DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DEBRISOQUINE 4 HYDROXYLASE;

ADULT; AGED; ALLELE; ARTICLE; CANCER EPIDEMIOLOGY; CANCER RISK; GENE LOCUS; GENETIC RISK; GENOTYPE; HOMOZYGOSITY; HUMAN; MAJOR CLINICAL STUDY; MALE; PHENOTYPE; PRIORITY JOURNAL; PROSTATE CANCER; STATISTICAL ANALYSIS;

ADULT; AGED; AGED, 80 AND OVER; ALLELES; CASE-CONTROL STUDIES; CYTOCHROME P-450 CYP2D6; DEBRISOQUIN; DNA PRIMERS; DNA, NEOPLASM; FEMALE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HUMANS; MALE; MIDDLE AGED; MUTATION; ODDS RATIO; PHENOTYPE; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; PROSTATIC NEOPLASMS; RISK FACTORS;

EID: 0032437677     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (9)

1. Smith, G., Stanley, L. A., Sim, D., Strange, R. C., and Wolf, C. R. Metabolic polymorphisms and cancer susceptibility. Cancer Surv., 23: 27-63, 1995.
2. Idle, J., and Smith, R. Polymorphisms of oxidation at carbon centers of drugs and their clinical significance. Drug Metab. Rev., 9: 301-317, 1979.
3. Mahgoub, A., Idle, J., Dring, L., Lancaster, R., and Smith, R. Polymorphic hydrozylarion of debrisoquine in man. Lancet, ii: 584-586, 1977.
4. Gonzalez, F., Skoda, R., Kimura, S., Umeno, M., Zanger, U. Neben, D., Gelboin, H., Hardwick, J., and Meyer, U. Characterization of the common genetic defect in humans deficient in debrisoquine metabolism. Nature (Lond.), 331: 442-446, 1988.
5. Eichelbaum, M. Polymorphic drug oxidation in humans. Fed. Proc., 43: 2298-2302, 1984.
6. Johansson, I., Lundqvist, E., Bertilsson, L., Dahl, M., Sjoqvist, F., and Ingleman-Sundberg, M. Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine. Proc. Natl. Acad. Sci. USA, 90: 11825-11829, 1993.
7. Ayesh, R., Idle, J., Ritchie, J., Crothers, M., and Hetzel, M. Metabolic oxidation phenotypes as markers for susceptibility to lung cancer. Nature (Lond.), 312: 169-171, 1984.
8. Sugimura, H., Caporaso, N., and Shaw, G. Human debrisoquine hydroxylase gene polymorphism in cancer patients and controls. Carcinogencsis (Lond.), 11: 1527-1530, 1990.
9. Kaisary, A., Smit, P., Jaczq, E., McAllister, C., Wilkinson, G., Ray, W., and Branch, R. Genetic predisposition to bladder cancer: ability to hydroxylate debrisoquine and mephenytoin as risk factors. Cancer Res., 47: 5488-5493, 1987.